On Sunday, April 20th 2025, starting 8:30am GMT, there will be maintenance work that will involve the website being unavailable during parts of the day. We apologize for any inconvenience this may cause and appreciate your understanding.
We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Opportunities for immunotherapy
- Cancer immunity cycle
- Many points for therapeutic intervention
- Four dominant approaches to immunotherapy
- Cytotoxic antibodies
- Antibiotic-drug conjugates in trials
- Currently approved mAb for cancer
- Cytotoxic antibodies: mechanisms of action
- Cytotoxic antibodies: Rituximab (a-CD20)
- Passive CTL immunotherapy
- CAR T cells: engineered targeting
- CAR T cells: Kymirah (a-CD19)
- Checkpoint blockade: anti-CTLA4
- Checkpoint blockade: Ipilimumab (a-CTLA-4)
- Checkpoint blockade: anti-PD1 and anti-PDL1
- Nivolumab (a-PD1) and Durvalumab (a-PDL1)
- Not all patients respond to treatment
- Vaccination
- Vaccination: therapeutic vaccines
- Cell based vaccine (DC)
- Therapeutic cancer vaccine: Sipuleucel-T
- Tumour specific neoantigens (1)
- Tumour specific neoantigens (2)
- Current immunotherapy development landscape
- Common toxicities
- Prospects for immunotherapy
- Thank you
Topics Covered
- Opportunities for immunotherapy
- Cytotoxic antibodies
- Monoclonal antibodies
- CAR T cells: engineered targeting
- Checkpoint blockade treatment
- Therapeutic vaccines
- Tumour specific neoantigens
- Current immunotherapy development landscape
Links
Series:
Categories:
Therapeutic Areas:
External Links
Talk Citation
Elliott, T. (2025, January 29). Cancer immunotherapy [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved April 15, 2025, from https://doi.org/10.69645/LGBZ2469.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Tim Elliott has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Other Talks in the Series: The Molecular Basis of Cancer
Other Talks in the Series: The Immune System - Key Concepts and Questions
Transcript
Please wait while the transcript is being prepared...
0:00
Hello, my name is Tim Elliott.
I'm the Kidani Professor of Immuno-oncology.
I work at the University of Oxford in the UK.
In this lecture, I'm going to give a brief introduction
to the basic principles of cancer immunotherapy.
I recommend you listen to an accompanying lecture in the same series here
on cancer immunology and this would serve as
a good primer to the lecture you're about to see now.
0:25
This cartoon describes in very basic terms,
the relationship between our immune system and a growing tumor.
We know that it's possible to prime T-cells to tumor antigens.
Those T-cells, when they become activated,
can home into the site of tumor development in a tissue where they
join other tissue-resident lymphocytes and together, these can kill tumor cells.
And that this process of tumor ablation can balance any cell division that's
occurring in tumor cells and a period of so-called tumor equilibrium can ensue.
We also know, however,
that tumors can escape this immune attack either by
inducing functional exhaustion in T-cells or by inducing
any immunosuppressive tumor microenvironment by attracting suppressive cells to
the microenvironment or by
reprogramming tissue-resident cells to become immunosuppressive.
Well, the tumors can simply lose the ability to
present and process antigens to those T-cell.
They escape simply because they become invisible and this then leads
to a period of tumor progression which is clinically potentially lethal.
Now, each one of these stages is a potential target for immunotherapy.
I'll go through these in turn throughout my lecture.